VNRX News and Press, VolitionRX Limited From 01/08/23

Volition Issues Business Review 2022 PR Newswire HENDERSON, Nev , Jan. 8, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2022, outlining its key highlights as the o...

Penny Stocks To Buy According To Insiders Whether you’re trading higher-priced or penny stocks, the year-end trends are mixed in 2022. While some may presume tax-loss selling is going to weigh heavier, others are loading up on their current holdings. In this article, we look at a few n...

Penny Stocks To Buy According to Company Insiders In December When you think about the end of the year, tax-loss selling is a more frequently discussed topic than loading up on penny stocks . But this isn’t an average year, and penny stocks are trading in typical conditions. As you...

VolitionRx Limited (VNRX) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM Company Participants Scott Powell - IR Cameron Reynolds - Founder, Group CEO Tom Butera - CEO, Volition Veterinary Terig Hughes - CFO Conference Call Participants ...

VolitionRX press release ( NYSE: VNRX ): Q3 Cash and cash equivalents as of September 30, 2022, totaled approximately $16.4 million compared with $16.7 million at the quarter ended June 30, 2022. Received approximately $6.4 million net of underwriter's fees and expenses in...

VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business Update PR Newswire Conference call to discuss financial and operational results scheduled for Tuesday, November 15 , at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev. ...

Volition Announces Clinical Research Study with Oncovet PR Newswire HENDERSON, Nev. , Nov. 14, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced a clinical research study with O...

VolitionRX ( NYSE: VNRX ) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$0.15 (-15.4% Y/Y) and the consensus Revenue Estimate is $0.1M (+233.3% Y/Y). Over the last 3 months, EPS estimates have ...

Volition to Participate in a Lung Cancer Screening Study in France PR Newswire HENDERSON, Nev. , Nov. 10, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has been invited to participat...

Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference Laboratories PR Newswire HENDERSON, Nev. , Nov. 3, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a mul...